Sometime within the next two years, clinical researchers are expected to begin inoculating at least 2000 African infants in the largest trial ever undertaken of an experimental vaccine for malaria. The planned efficacy trial will mark a milestone in the multidecade effort to make a vaccine against one of the world's greatest killers of children. It also represents a high-stakes gamble for the company hoping to license the product, GlaxoSmithKline Biologicals, as well as for funding agencies and the international research community. If the vaccine — known as RTS,S — is found to reduce significantly the rates of death and . . .
No takes yet. Share an insight, caveat, or question.
Susan Okie (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: